Xtandi Astellas Pharma Australia Pty Ltd
Product name
Xtandi
Accepted date
Jan-2024
Active ingredients
enzalutamide
Proposed indication
The treatment of non metastatic hormone-sensitive prostate cancer (nmHSPC).
Application type
C (new indication)
Publication date
Jan-2024